KCT0007496尚未招募未知
The safety and efficacy of first line palliative chemotherapy and Korean medicine including Rhus verniciflua stokes for patients with unresectable advanced pancreatic cancer or metastatic pancreatic cancer: a prospective observational preliminary study
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •19 years of age or older
- •Pancreatic cancer (neoplasm) was confirmed by biopsy
- •Who are diagnosed as stage 3 or 4 of TNM staging based on the 8th edition of the AJCC, and are inoperable
- •Who are scheduled for combination treatment with 5-FU or gemcitabine-based/mono first palliative chemotherapy and traditional Korean medicine including Rhus verniciflua stokes or within 2 months of starting the treatment
- •Whose life expectancy is more than 3 months
- •The Eastern Cooperative Oncology Group (ECOG) performance status score 0-2
- •Those who understand the research content and agree to participate in the research
排除标准
- •Pregnant women, lactating women
- •Patients with active brain metastases showing clinically significant neurological symptoms or signs
- •Those who have clinically significant skeletal related events, including pathological fractures and spinal cord compressions, and require radiotherapy or surgical therapy
- •Those who have been diagnosed with other new primary cancers that may affect the patient's condition within the last 5 years
- •Who are judged to be inappropriate for the research
研究者
相似试验
已完成
2 期
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): a phase II trialChronic Lymphatic Leukemia10024324CLLNL-OMON36713HOVO62
已完成
2 期
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.Burkitt lymphomahighly aggressive B cell lymphoma10025320NL-OMON36941Vrije Universiteit Medisch Centrum22
进行中（未招募）
不适用
A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.Burkitt lymphomaMedDRA version: 14.1Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2012-003141-16-NLVU University Medical Center
已完成
4 期
Efficacy and safety of the medications of first line treatment (artesunate+amodiaquine) and second line treatment (artemether+lumefantrine) for the treatment of uncomplicated Plasmodium falciparum in Malabo, Bata and Ebibey, Equatorial GuineeMalariaACTRN12617000456358Ministry of Public Health of Equatorial Guinea528
已完成
不适用
A randomised phase 3 trial of Palliative care Early in Advanced Lung Cancers.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Cancer - Lung - Small cellCancer - Lung - Non small cellCancer - Lung - MesotheliomaACTRN12617000166370niversity of Sydney113